NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT With Brachytherapy in Patients With Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated With Androgen Deprivation
Sponsor: Nanobiotix
Terminated
Prostate cancer treatment has greatly changed since the initiation of this trial and therefore we have stopped this trial to allow for further evaluation of the treatment landscape
Other terminated trials from Nanobiotix
More terminations from Nanobiotix
Other Prostate Cancer trials with similar outcome
This PHASE1/PHASE2 trial investigates Prostate Cancer and is currently terminated or withdrawn. Nanobiotix leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2021 — Dec 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
May 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2018 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nanobiotix
For direct contact, visit the study record on ClinicalTrials.gov .